<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815265</url>
  </required_header>
  <id_info>
    <org_study_id>NKYY_YWKT_IRB_2020_007_01</org_study_id>
    <nct_id>NCT04815265</nct_id>
  </id_info>
  <brief_title>Remimazolam for Sedation in ICU Patients Undergoing Mechanical Ventilation</brief_title>
  <official_title>Efficacy and Safety of Remimazolam for Sedation in ICU Patients Undergoing Mechanical Ventilation: a Single Center, Randomized, Controlled, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Nankai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Nankai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sedation is a component of the care of critically ill patients who are undergoing mechanical&#xD;
      ventilation. Dexmedetomidine induces sedation while preserving a degree of arousability among&#xD;
      patients in the intensive care unit (ICU), and its use has resulted in a shorter time to&#xD;
      extubation, an increased number of days free from coma or delirium, a reduced incidence of&#xD;
      agitated delirium, prevention of delirium, and lower mortality than other agents administered&#xD;
      in certain populations. Hypotension and bradycardia are common side effects, which is lethal&#xD;
      for the patients with persistent or severe hemodynamic instability.&#xD;
&#xD;
      The pharmacological properties of rimazolom suggest that it is an ideal sedative drug for&#xD;
      critically ill patients, but there is no relevant clinical research to confirm it. Therefore,&#xD;
      this study mainly discusses the efficacy and safety of remidazolam in ICU patients with&#xD;
      mechanical ventilation, so as to provide theoretical basis for individualized sedation&#xD;
      treatment of patients with mechanical ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Title: Efficacy and Safety of Remimazolam for Sedation in ICU Patients Undergoing&#xD;
           Mechanical Ventilation&#xD;
&#xD;
        2. Research center: Single Center&#xD;
&#xD;
        3. The Design of the study: Randomized, Controlled, Non-inferiority Trial&#xD;
&#xD;
        4. The population of the study: The main inclusion criteria are 18 years old or above,&#xD;
           invasive mechanical ventilation is required, and the clinical need is mild to moderate&#xD;
           Sedated (RASS score 0 to -3) patients&#xD;
&#xD;
        5. Sample size: Enroll 488 patients (244patients in each group)&#xD;
&#xD;
        6. Interventions: Participants in the test group received remimazolam for sedation, while&#xD;
           participants in the control group received dexmedetomidine, The analgesia drug in two&#xD;
           group is fentanyl.&#xD;
&#xD;
        7. The aim of the research: To investigate the efficacy and safety of remimazolam for&#xD;
           sedation in ICU patients undergoing mechanical ventilation&#xD;
&#xD;
        8. Outcome# 1) Primary outcome# the ratio of the time to reach the target sedation (RASS&#xD;
           score, 0 to -3)in the total duration of drug infusion, and the duration of mechanical&#xD;
           ventilation. 2)Secondary outcome#; Length of stay in ICU and Length of stay in hospital;&#xD;
           Incidence of complications (including re-hospitalization); Total expenses during&#xD;
           hospitalization&#xD;
&#xD;
        9. The estimated duration of the study#2-3years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to reach targeted sedation goals</measure>
    <time_frame>an average of 1-2 year</time_frame>
    <description>the ratio of the time to reach the target sedation (RASS score, 0 to -3) in the total duration of drug infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the duration of mechanical ventilation</measure>
    <time_frame>average of 1-2 year</time_frame>
    <description>Duration of mechanical ventilation in ICU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>2 years</time_frame>
    <description>Length of stay in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>about 2 years</time_frame>
    <description>Length of stay in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total expenses during hospitalization</measure>
    <time_frame>24 months</time_frame>
    <description>Total expenses during hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">488</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the experimental group received remimazolam for sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants in the control group received dexmedetomidine for sedation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <description>Remimazolam is used for sedation</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine is used for sedation</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The main inclusion criteria are 18 years old or above, invasive mechanical ventilation is&#xD;
        required, and the clinical need is mild to moderate Sedated (RASS score 0 to -3) patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refuse to participate in this study&#xD;
&#xD;
          2. Patients with severe bradycardia (HR&lt;50 bpm)&#xD;
&#xD;
          3. Patients who is pregnancy&#xD;
&#xD;
          4. Patients with brain injury or neurosurgery&#xD;
&#xD;
          5. Patients receiving sedation for treatment indications (such as epilepsy), not to&#xD;
             tolerate a ventilator.&#xD;
&#xD;
          6. Patients receiving any study medication within 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianbo Yu</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Nankai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan Zhang, PHD</last_name>
    <phone>13642066361</phone>
    <email>13642066361@126.com</email>
  </overall_contact>
  <reference>
    <citation>Shehabi Y, Chan L, Kadiman S, Alias A, Ismail WN, Tan MA, Khoo TM, Ali SB, Saman MA, Shaltut A, Tan CC, Yong CY, Bailey M; Sedation Practice in Intensive Care Evaluation (SPICE) Study Group investigators. Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study. Intensive Care Med. 2013 May;39(5):910-8. doi: 10.1007/s00134-013-2830-2. Epub 2013 Jan 24.</citation>
    <PMID>23344834</PMID>
  </reference>
  <reference>
    <citation>Barr J, Fraser GL, Puntillo K, Ely EW, GÃ©linas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, Coursin DB, Herr DL, Tung A, Robinson BR, Fontaine DK, Ramsay MA, Riker RR, Sessler CN, Pun B, Skrobik Y, Jaeschke R; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013 Jan;41(1):263-306. doi: 10.1097/CCM.0b013e3182783b72. Review.</citation>
    <PMID>23269131</PMID>
  </reference>
  <results_reference>
    <citation>Shehabi Y, Howe BD, Bellomo R, Arabi YM, Bailey M, Bass FE, Bin Kadiman S, McArthur CJ, Murray L, Reade MC, Seppelt IM, Takala J, Wise MP, Webb SA; ANZICS Clinical Trials Group and the SPICE III Investigators. Early Sedation with Dexmedetomidine in Critically Ill Patients. N Engl J Med. 2019 Jun 27;380(26):2506-2517. doi: 10.1056/NEJMoa1904710. Epub 2019 May 19.</citation>
    <PMID>31112380</PMID>
  </results_reference>
  <results_reference>
    <citation>Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012 Aug;115(2):274-83. doi: 10.1213/ANE.0b013e31823f0c28. Epub 2011 Dec 20.</citation>
    <PMID>22190555</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Nankai Hospital</investigator_affiliation>
    <investigator_full_name>Jianbo Yu</investigator_full_name>
    <investigator_title>Department of Anesthesiology and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

